Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FlyteHealth vs Vita Bella

FlyteHealth
Graded #364

Lower grade

vs+6.300000000000004
Vita Bella
Graded #233

Higher grade

The verdict

Vita Bella takes it — 64.9/100 to 58.6/100.

Vita Bella grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vita Bella is a Nevada-based telehealth membership platform (Vita Bella Health, LLC) that offers compounded GLP-1 weight-loss medications alongside hormone therapy, peptides, sexual-wellness and anti-aging…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFlyteHealth +1
45
44
Dose & formulationVita Bella +12
40
52
Clinical oversightVita Bella +8
83
91
Labs & monitoringVita Bella +4
73
77
FulfillmentVita Bella +21
62
83
Contract termsFlyteHealth +8
55
47
FlyteHealth · left barVita Bella · right bar

The numbers

MetricFlyteHealthVita Bella
WeighScore58.6/10064.9/100
GradeCC
Scorecard rank#364#233
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosed$159/mo (2.5 mg dose, plus a separate fee, compounded)
CoverageCoverage not published46 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FlyteHealth

Graded #364 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1
Vita Bella

Graded #233 · C

Strengths

  • Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
  • Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
  • Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
  • Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
  • Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge

Where it loses points

  • Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
  • Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
  • Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard